Nevin de Korompay (@nevdek) 's Twitter Profile
Nevin de Korompay

@nevdek

UBC KGH Interventional Radiology #IRad

ID: 840267682666569729

calendar_today10-03-2017 18:26:41

1,1K Tweet

770 Takipçi

554 Takip Edilen

Jack Garnham (@jjgarnham) 's Twitter Profile Photo

This patient presented with a classic aneurysmal subarachnoid haemorrhage. We couldn't find an aneurysm on CTA, MRA, or DSA... but on a subsequent black-blood MRA there was a tiny fleck of enhancement in the region of the ACOM. On repeat DSA, this turned out to be a tiny

This patient presented with a classic aneurysmal subarachnoid haemorrhage. We couldn't find an aneurysm on CTA, MRA, or DSA... but on a subsequent black-blood MRA there was a tiny fleck of enhancement in the region of the ACOM. On repeat DSA, this turned out to be a tiny
JNIS (@jnis_bmj) 's Twitter Profile Photo

Do you know what you are measuring? Dynamic head rotation can dramatically alter intracranial venous pressure measurements, indicating single position lumbar puncture opening pressure may not tell the whole story! bit.ly/4l7y4Hr #ICP #JugularStenosis

Do you know what you are measuring?  Dynamic head rotation can dramatically alter intracranial venous pressure measurements, indicating single position lumbar puncture opening pressure may not tell the whole story! bit.ly/4l7y4Hr #ICP #JugularStenosis
Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️ On NEJM - Bevacizumab + Erlotinib shows clinical activity in both hereditary and sporadic papillary renal cell carcinoma. Confirmed response: - 72% in HLRCC-associated - 35% in sporadic cases #kidneycancer nejm.org/doi/full/10.10…

⚡️ On <a href="/NEJM/">NEJM</a> - Bevacizumab + Erlotinib shows clinical activity in both hereditary and sporadic papillary renal cell carcinoma.
Confirmed response:

- 72% in HLRCC-associated
- 35% in sporadic cases

#kidneycancer 

nejm.org/doi/full/10.10…
Wil (@willyrontgen) 's Twitter Profile Photo

Vomiting up the entire Fleischner criteria guidelines in the impression of your report is lazy and helps no one. Just give the specific, appropriate recommendation for follow up.

Vomiting up the entire Fleischner criteria guidelines in the impression of your report is lazy and helps no one. Just give the specific, appropriate recommendation for follow up.
Jacob Fleming, MD (@jacobflemingmd) 's Twitter Profile Photo

Curved needles and cement cannulas are helpful for targeting focal fracture clefts. Small T8 superior endplate cleft after otherwise sufficient kypho at OSH was not amenable to pedicular access. Transdiscal access from above made for an easy fix.

Curved needles and cement cannulas are helpful for targeting focal fracture clefts. Small T8 superior endplate cleft after otherwise sufficient kypho at OSH was not amenable to pedicular access. Transdiscal access from above made for an easy fix.
PERT Consortium (@pertconsortium) 's Twitter Profile Photo

We’re excited to share enrollment for HI-PEITHO is now complete! With 544 patients enrolled across 72 sites in the United States in Europe, this landmark trial compares EKOS (Ultrasound Assisted Thrombolysis) with Anticoagulation vs Anticoagulation Alone in the treatment of

We’re excited to share enrollment for HI-PEITHO is now complete! With 544 patients enrolled across 72 sites in the United States in Europe, this landmark trial compares EKOS (Ultrasound Assisted Thrombolysis) with Anticoagulation vs Anticoagulation Alone in the treatment of
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Updated results from KEYNOTE-B61: First-line pembrolizumab + lenvatinib in advanced non-clear-cell RCC shows: ✅ ORR 51% ✅ CR in 8.2% ✅ Median DOR 19.5 mo A promising option for nccRCC. #oncology #kidneycancer European Urology Laurence Albiges OncoAlert Uromigos pubmed.ncbi.nlm.nih.gov/40707309/

Updated results from KEYNOTE-B61:
First-line pembrolizumab + lenvatinib in advanced non-clear-cell RCC shows:
✅ ORR 51%
✅ CR in 8.2%
✅ Median DOR 19.5 mo
A promising option for nccRCC.
#oncology #kidneycancer <a href="/EUplatinum/">European Urology</a> <a href="/AlbigesL/">Laurence Albiges</a> <a href="/OncoAlert/">OncoAlert</a> <a href="/Uromigos/">Uromigos</a> 
pubmed.ncbi.nlm.nih.gov/40707309/
Derek W. Cool, MD, PhD (@derekwcool) 's Twitter Profile Photo

The phase II ARRCC trial has opened and enrolling its first patients for treatment of non-metastatic RCC. Excited to see if selective internal radiation therapy with Y-90 radioembolization can benefit RCC patients! authors.elsevier.com/a/1lUCL3k%7EjJ… #iRad #RCC Canadian Urological Association Canadian Association for Interventional Radiology

Dr Amine Korchi (@aminekorchimd) 's Twitter Profile Photo

Pay radiologists per case, and they’ll fight for volume. Pay them a salary, and suddenly they’re “not qualified enough” to read half the exams. Incentives shape behavior !

Shuo (Chris) Li (@vir_li) 's Twitter Profile Photo

PT with aortoiliac stents and occluded L IIA. Lots of cross pelvic collaterals with the right prostate artery filling the left prostate artery. Two vessels, one catheter. #PAE #irad Society of Interventional Radiology

PT with aortoiliac stents and occluded L IIA. Lots of cross pelvic collaterals with the right prostate artery filling the left prostate artery. Two vessels, one catheter. #PAE #irad <a href="/SIRspecialists/">Society of Interventional Radiology</a>
Endovascular Today (@evtoday) 's Twitter Profile Photo

Lakshmi A. Ratnam, MBChB, discuses the evolving technique of bleomycin electrosclerotherapy (BEST) for low-flow vascular malformations, guidance on the importance of a dedicated BEST team, tips for female interventional radiology trainees, & more evtoday.com/articles/2025-…

Alessandro Vitale (@vaital73) 's Twitter Profile Photo

🧠 Cancer responds. Surgeons wait. Patients lose. In our new Converse Study (n=2,379 HCC patients), 16% responded well enough to be potentially cured after Atezolizumab+Bevacizumab. But only 3% actually received curative treatment. We call this the under-conversion gap:

🧠 Cancer responds. Surgeons wait. Patients lose.

In our new Converse Study (n=2,379 HCC patients), 16% responded well enough to be potentially cured after Atezolizumab+Bevacizumab.

But only 3% actually received curative treatment.

We call this the under-conversion gap:
Mustafa Al-Roubaie (@alroubaiemd) 's Twitter Profile Photo

After injecting 2cc of 100-300um Embosphere solution (2cc particles diluted in 10cc contrast), I noticed no tactile slowing of flow w/ flushing. In this territory that is a red flag. DSA then showed contrast flowing into the subdural drain😂Merit Medical Daryl Goldman MD #MMA #irad

After injecting 2cc of 100-300um Embosphere solution (2cc particles diluted in 10cc contrast), I noticed no tactile slowing of flow w/ flushing. In this territory that is a red flag. DSA then showed contrast flowing into the subdural drain😂<a href="/MeritMedical/">Merit Medical</a> <a href="/Daryl_Goldman/">Daryl Goldman MD</a> #MMA #irad